Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease
Yıl: 2019 Cilt: 30 Sayı: 12 Sayfa Aralığı: 1025 - 1029 Metin Dili: İngilizce DOI: 10.5152/tjg.2019.19346 İndeks Tarihi: 17-07-2020
Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease
Öz: Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatorybowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13)in patients with IBD and to assess their possible role in the etiopathogenesis of the disease.Materials and Methods: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn’s disease) and 20 healthy controls were included in the present study. TAFI, TFPI, and ADAMTS-13 concentrations were determined by enzyme-linked immunosorbent assay.Results: Mean TAFI, TFPI, and ADAMTS-13 concentrations in the patient group were 17.75 ng/ml, 72.10 ng/ml, and 14.90 U/l, respectively. In the control group, these values were 117.10 ng/ml, 300 ng/ml, and 191.55 U/l, respectively. TAFI, TFPI, and ADAMTS-13 values weresignificantly lower in the patient group than in the control group (all p<0.01).Conclusion: TAFI, TFPI, and ADAMTS-13 levels were significantly lower in the patient group. These findings indicate the presence of aclear, multifactorial imbalance in the coagulation–fibrinolytic system in the patient group. It is also possible that this imbalance in thecoagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bernhard H, Deutschmann A, Leschnik B, et al. Thrombin generation in pediatric patients with Crohn’s disease. Inflamm Bowel Dis 2011; 17: 2333-9. [CrossRef]
- 2. Maher MM, Soloma SH. Assesment of thrombophilic abnormalities during the active state of inflammatory bowel disease. Saudi J Gastroenterol 2008; 14: 192-7. [CrossRef]
- 3. Said Y, Hamzaoui L, El Jeri K, et al. Prevalence and risk factors of thromboembolic complications in inflammatory bowel disease. Tunis Med 2011; 89: 924-8.
- 4. Dogan Y, Soylu A, Eren GA, et al. Evaluation of QT and P wave dispersion and mean platelet volume among inflammatory bowel disease patients. Int J Med Sci 2011; 8: 540-6. [CrossRef]
- 5. Hall CL, Zaman FS. A computational analysis of an in vitro vessel wall injury model. Ann Biomed Eng 2012; 40:1486-94. [CrossRef]
- 6. Holroyd EW, White TA, Pan S, Simari RD. Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure. Front Biosci 2012; 4: 392-400. [CrossRef]
- 7. Lippi G, Favaloro EJ. Coagulopathies and thrombosis: usual and unusual cuses and associations, part VI. Semin Thromb Hemost 2012; 38: 125-8. [CrossRef]
- 8. Winckers K, Siegerink B, Duckers C, et al. Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. J Thromb Haemost 2011; 9: 2243-50. [CrossRef]
- 9. Peraramelli S, Rosing J, Hackeng TM. TFPI-dependent activities of protein S. Thromb Res 2012: 129: 23-6. [CrossRef]
- 10. Reichman-Warmusz E, Kurek J, Gabriel A, et al. Tissue hemostasis and chronic inflammation in colon biopsies of patients with inflammatory bowel disease. Pathol Res Pract 2012; 208: 553-6. [CrossRef]
- 11. Reijerkerk A, Voest EE, Gebbink MF. No grip, no growth: The conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 2000; 36: 1695-705. [CrossRef]
- 12. Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinoliysis and inflammation. Thromb Res 2012; 129: 314-9. [CrossRef]
- 13. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-40. [CrossRef]
- 14. Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013; 11: 11-23. [CrossRef]
- 15. Edwards NC, Hing ZA, Perry A, et al. Characterization of coding synonymous and non-synonymous vairants in ADAMTS13 using ex vivo and silico approaches. Plos One 2012; 7: e38864. [CrossRef]
- 16. Yuan H, Deng N, Zhang S, et al. The unfolded von Willebrand factor response in bloodstream: the self-association perspective. J Hematol Oncol 2012; 5: 65. [CrossRef]
- 17. Rossio R, Ferrai B, Cairo A, et al. Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura. Blood Transfus 2013; 11: 241-4.
- 18. Bender M. High VWF, low ADAMTS13 puts women at risk. Blood 2012; 119: 1329-30. [CrossRef]
- 19. Alkim H, Ayaz S, Alkim C, Ulker A, Sahin B. Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease. Clin Appl Thromb Hemost 2011; 17: 600-4. [CrossRef]
- 20. Danese S, Papa A. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. Eur J Gastroenterol Hepatol 2008; 20: 826-8. [CrossRef]
- 21. Gao YH, Gao PJ, Wang CG, Wang XC, Piao YF. Relationship and significance between anti-beta2-glycoprotein 1 antibodies and platelet activation state in patients with ulcerative colitis. World J Gastroenterol 2008; 14: 771-5. [CrossRef]
- 22. Zitomersky NL, Verhave M, Trenor CC 3rd. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis 2011; 17: 458-70. [CrossRef]
- 23. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106: 713-8. [CrossRef]
- 24. Ennaifer R, Moussa A, Mouelhi L, et al. Cerebral venous sinus thrombosis as presenting feature of ulcerative colitis. Acta Gastroenterol Belg 2009; 72: 350-3.
- 25. Sam JJ, Bernstein CN, Razik R, Thanabalan R, Nguyen GC. Physicians’ perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci 2012; 58: 46-52. [CrossRef]
- 26. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174-86. [CrossRef]
- 27. Suárez Ferrer C, Vera Mendoza MI, Amo San Román L, et al. Risk of thromboembolic phenomena in patients with inflammatory bowel disease. Gastroenterol Hepatol 2012; 35: 634-9. [CrossRef]
- 28. Deng X, Szabo S, Khomenko T, et al. Novel pharmacologic approaches to the prevention and treatment of ulcerative colitis. Curr Pharm Des 2013; 19: 17-28. [CrossRef]
- 29. He HL, Zhang JB, Li Q. Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis. World J Gastroenterol 2014; 20: 7461. [CrossRef]
- 30. Koutrovbakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA. Plasma thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitör-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008; 20: 912-6. [CrossRef]
- 31. Declerck PJ. Thrombin activatable fibrinolysis inhibitor. Hamostaseologie 2011; 31: 165-6, 168-73. [CrossRef]
- 32. Owczarek D, Undas A, Foley JH, Nesheim ME, Jabłonski K, Mach T. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD. J Crohns Colitis 2012; 6: 13-20. [CrossRef]
- 33. Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma fibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-21. [CrossRef]
- 34. Zitomersky NL, Demers M, Martinod K, et al. ADAMTS13 Deficiency Worsens Colitis and Exogenous ADAMTS13 Administration Decreases Colitis Severity in Mice. TH Open. 2017; 1: e11-e23. [CrossRef]
| APA | YÜZBAŞIOĞLU B, Ustaoglu M, YÜZBAŞIOĞLU Ş, Akbulut U, ÖZDİL K (2019). Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. , 1025 - 1029. 10.5152/tjg.2019.19346 |
| Chicago | YÜZBAŞIOĞLU Bilgehan,Ustaoglu Muge,YÜZBAŞIOĞLU Şule,Akbulut Ulas Emre,ÖZDİL Kamil Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. (2019): 1025 - 1029. 10.5152/tjg.2019.19346 |
| MLA | YÜZBAŞIOĞLU Bilgehan,Ustaoglu Muge,YÜZBAŞIOĞLU Şule,Akbulut Ulas Emre,ÖZDİL Kamil Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. , 2019, ss.1025 - 1029. 10.5152/tjg.2019.19346 |
| AMA | YÜZBAŞIOĞLU B,Ustaoglu M,YÜZBAŞIOĞLU Ş,Akbulut U,ÖZDİL K Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. . 2019; 1025 - 1029. 10.5152/tjg.2019.19346 |
| Vancouver | YÜZBAŞIOĞLU B,Ustaoglu M,YÜZBAŞIOĞLU Ş,Akbulut U,ÖZDİL K Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. . 2019; 1025 - 1029. 10.5152/tjg.2019.19346 |
| IEEE | YÜZBAŞIOĞLU B,Ustaoglu M,YÜZBAŞIOĞLU Ş,Akbulut U,ÖZDİL K "Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease." , ss.1025 - 1029, 2019. 10.5152/tjg.2019.19346 |
| ISNAD | YÜZBAŞIOĞLU, Bilgehan vd. "Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease". (2019), 1025-1029. https://doi.org/10.5152/tjg.2019.19346 |
| APA | YÜZBAŞIOĞLU B, Ustaoglu M, YÜZBAŞIOĞLU Ş, Akbulut U, ÖZDİL K (2019). Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. Turkish Journal of Gastroenterology, 30(12), 1025 - 1029. 10.5152/tjg.2019.19346 |
| Chicago | YÜZBAŞIOĞLU Bilgehan,Ustaoglu Muge,YÜZBAŞIOĞLU Şule,Akbulut Ulas Emre,ÖZDİL Kamil Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. Turkish Journal of Gastroenterology 30, no.12 (2019): 1025 - 1029. 10.5152/tjg.2019.19346 |
| MLA | YÜZBAŞIOĞLU Bilgehan,Ustaoglu Muge,YÜZBAŞIOĞLU Şule,Akbulut Ulas Emre,ÖZDİL Kamil Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. Turkish Journal of Gastroenterology, vol.30, no.12, 2019, ss.1025 - 1029. 10.5152/tjg.2019.19346 |
| AMA | YÜZBAŞIOĞLU B,Ustaoglu M,YÜZBAŞIOĞLU Ş,Akbulut U,ÖZDİL K Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. Turkish Journal of Gastroenterology. 2019; 30(12): 1025 - 1029. 10.5152/tjg.2019.19346 |
| Vancouver | YÜZBAŞIOĞLU B,Ustaoglu M,YÜZBAŞIOĞLU Ş,Akbulut U,ÖZDİL K Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. Turkish Journal of Gastroenterology. 2019; 30(12): 1025 - 1029. 10.5152/tjg.2019.19346 |
| IEEE | YÜZBAŞIOĞLU B,Ustaoglu M,YÜZBAŞIOĞLU Ş,Akbulut U,ÖZDİL K "Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease." Turkish Journal of Gastroenterology, 30, ss.1025 - 1029, 2019. 10.5152/tjg.2019.19346 |
| ISNAD | YÜZBAŞIOĞLU, Bilgehan vd. "Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease". Turkish Journal of Gastroenterology 30/12 (2019), 1025-1029. https://doi.org/10.5152/tjg.2019.19346 |
